• Search chemicals, activators, Inhibitors, APIs, intermediates and raw materials.

828934-41-4 ((R)-(+)-Etomoxir (sodium salt))

1

Identification

(R)-(+)-Etomoxir (sodium salt) (R)-(+)-Etomoxir (sodium salt)
Name (R)-(+)-Etomoxir (sodium salt)
Formula C15H18ClNaO4
MW 320.74
CAS No. 828934-41-4
EINECS
Smiles ClC1=CC=C(OCCCCCC[[email protected]@]2(CO2)C([O-])=O)C=C1.[Na+]
Synonyms (+)-Etomoxir sodium salt; sodium (R)-2-(6-(4-chlorophenoxy)hexyl)oxirane-2-carboxylate
InChI InChI=1S/C15H19ClO4.Na/c16-12-5-7-13(8-6-12)19-10-4-2-1-3-9-15(11-20-15)14(17)18;/h5-8H,1-4,9-11H2,(H,17,18);/q;+1/p-1/t15-;/m1./s1
2

Introduction

(R)-(+)-Etomoxir (sodium salt) is a potent inhibitor of carnitine palmitoyltransferase I (CPT1); inhibits β-oxidation in mitochondria; shown to inhibit cardiolipin biosynthesis from exogenous fatty acid in H9c2 cells.

Background Information

Irreversible inhibitor of carnitine palmitoyltransferase-1 (CPT-1a) a mitochondrial enzyme involved in fatty acid β-oxidation. CPR-1a on the outer face of the inner mitochondrial membrane, consequently prevents the formation of acyl carnitines, a step that is necessary for the transport of fatty acyl chains from the cytosol into the intermembrane space of the mitochondria, essential for the production of ATP from fatty acid oxidation. Fatty acid β-oxidation (FAO) inhibitor. By regulating fatty acid oxidation it has hypoketonaemic, hypocholesteraemic and hypolipogenic effect, and the potential to affect ketogenesis, cholesterol synthesis and gluconeogenesis. Useful agent for immunometabolism research. Anticancer, antiobesity and antidiabetes agent. Increases food intake and reduces hepatic ATP/ADP ratio. Mitochondrial fatty acid oxidation may provide NADPH for defense against oxidative stress and prevent ATP loss and cell death. PPARα activator/agonist. Shows non-specific effects on oxidative metabolism and cellular redox and induces acute production of ROS with associated evidence of severe oxidative stress in proliferating T cells at above 5μM concentration. Shown to have potentiating effects on chemotherapeutic agents. ......by Adipogen Corporation
Etomoxir is an inhibitor of carnitine palmitoyltransferase A (CPT1), which is required for the oxidation of long-chain acyl CoA esters. Also a strong inhibitor of mitochondrial CPT1 and a candidate as an anti-diabetic drug. ......by AdooQ BioScience, LLC
(R)-((addition))-Etomoxir sodium salt is a potent inhibitor of carnitine palmitoyltransferase I (CPT1), which inhibits β-oxidation in mitochondria. It has shown to inhibit cardiolipin biosynthesis from exogenous fatty acid in H9c2 cells. ......by BOC Sciences
(R)-(+)-Etomoxir sodium salt is R-form of Etomoxir sodium salt. Etomoxir is a potent inhibitor of carnitine palmitoyltransferase-I (CPT-1). ......by MedChemexpress Co., Ltd.
Etomoxir is an irreversible inhibitor of carnitine palmitoyltransferase-1 (CPT-1) on the outer face of the inner mitochondrial membrane. This prevents the formation of acyl carnitines, a step that is necessary for the transport of fatty acyl chains from the cytosol into the intermembrane space of the mitochondria. This step is essential to the production of ATP from fatty acid oxidation. Etomoxir has also been identified as a direct agonist of PPARα. ......by MedKoo Biosciences, Inc.
Etomoxir is an irreversible inhibitor of carnitine palmitoyltransferase-1 (CPT-1) on the outer face of the inner mitochondrial membrane. ......by Selleck Chemicals LLC
3

Protocol(Only for Reference)

Cell Experiment

Animal Experiment

4

Physical and Chemical Properties

Appearance:White to off-white Solid EBNumber:EB000010012

Storage condition

Solubility

5

Mechanism and Indication

Signaling Pathways Others
Target Others
Research Area Metabolic Disease
Indications
6

Clinical Information

Product Name Sponsor & Collaborators Indications Start Date End Date Phase
(R)-(+)-Etomoxir (sodium salt) - Not Found
(R)-(+)-Etomoxir (sodium salt) - No Development Reported
7

Safety Data of (R)-(+)-Etomoxir (sodium salt)

8

Spectral Information

9

Suppliers List

Company Price and Availability Country/Region
Adipogen Corporation USA
AdooQ BioScience, LLC USA
Apexbio Technology LLC USA
Ark Pharm, Inc. USA
BOC Sciences
Biochempartner Co., Ltd China
CHEMSCENE, LLC 5mg/USD84();10mg/USD144() USA
Cayman Chemical Company 5mg/USD85() USA
DC Chemicals 100mg/USD700() China
MedChemexpress Co., Ltd. 5mg/USD84();10mg/USD144() USA
MedKoo Biosciences, Inc. USA
Santa Cruz Biotechnology, Inc. 5mg/USD139() USA
Selleck Chemicals LLC USA
Shanghai Haoyuan Chemexpress Co., Ltd. 5mg/USD84();10mg/USD144() China
Tocris Bioscience Inc. 10mg/USD165() USA
10

Related Products

Other Forms of 828934-41-4

Name CAS No Formula MW
(R)-(+)-Etomoxir (sodium salt hydrate) 1049724-28-8 C15H20ClNaO5 338.76
Etomoxir 124083-20-1 C17H23ClO4 326.82

Recommended Compounds in Others

Name CAS No Formula MW
Dictamine 484-29-7 C12H9NO2 199.21
3,3',5-Triiodo-L-thyronine (sodium) 55-06-1 C15H11I3NNaO4 672.9553
Fabomotizole (hydrochloride) 173352-39-1 C15H22ClN3O2S 343.8721
FPH2 957485-64-2 C14H16ClN5O2S 353.83
α-Tocopherol (phosphate) 38976-17-9 C29H51O5P 510.69
BAMB-4 891025-25-5 C15H12N2O2 252.27
LDN-27219 312946-37-5 C20H16N4O2S2 408.5
ISO-1 478336-92-4 C12H13NO4 235.24
Aurothioglucose 12192-57-3 C6H11AuO5S 392.18
Oxybenzone 131-57-7 C14H12O3 228.24
ITX3 347323-96-0 C22H17N3OS 371.45
Cardiogreen 3599-32-4 C43H47N2NaO6S2 774.96
Skp2 Inhibitor C1 432001-69-9 C18H13BrN2O4S2 465.34
INH1 313553-47-8 C18H16N2OS 308.4
PF6-AM 1268491-69-5 C33H31BO12 630.4
XEN445 1515856-92-4 C18H17F3N2O3 366.33
Disperse Blue 148 52239-04-0 C19H19N5O4S 413.45026
Solvent Blue 35 17354-14-2 C22H26N2O2 350.454
CID-797718 370586-05-3 C12H11NO3 217.2206
CP-640186 (hydrochloride) 591778-70-0 C30H36ClN3O3 522.08

Recommended Compounds in Same Indication

Name CAS No Formula MW
11

Route of Synthesis

12

References

13

More Information

(R)-(+)-Etomoxir (sodium salt)

Tags: buy 828934-41-4 IC50 | 828934-41-4 price | 828934-41-4 cost | 828934-41-4 solubility | 828934-41-4 purchase | 828934-41-4 manufacturer | 828934-41-4 research buy | 828934-41-4 order | 828934-41-4 MSDS | 828934-41-4 chemical structure | 828934-41-4 Storage condition | 828934-41-4 molecular weight | 828934-41-4 mw | 828934-41-4 datasheet | 828934-41-4 supplier | 828934-41-4 cell line | 828934-41-4 NMR | 828934-41-4 MS | 828934-41-4 IR | 828934-41-4 solubility | 828934-41-4 Safe information | 828934-41-4 Qc and Spectral Information | 828934-41-4 Clinical Information | 828934-41-4 Clinical Trial | 828934-41-4 Route of Synthesis | 828934-41-4 storage condition | 828934-41-4 diseases and conditions | 828934-41-4 flash point | 828934-41-4 boiling point | 828934-41-4 melting point | 828934-41-4 storage condition | 828934-41-4 brand